1. Progress in Introduction of Pneumococcal Conjugate Vaccine — Worldwide, 2000–2012. Morbidity and Mortality Weekly Report. April 26, 2013 / Vol. 62 / No. 16
2.Deloria MK, Daniel EP, Scott T J, Chandir S, Aletta S , Laura NC, Katherine E. Dutra F, D Jennifer, Goldblatt, D, G Cynthia and O’Brien KL. Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Immunogenicity (Pediatr Infect Dis J 2014; 33:S119–S129.
3.Expert committee on biological standardization, Geneva, 19 to 2 October 2009. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccine. (http://www.int/biologicals/areas/vaccines/pneumo/Pneumo final 23 april 2010.pdf, consultado en marzo de 2012.
4.Silfverdal SA, Flodmark CE, Rombo L, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in children partially immuized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial. Vaccine 2013; 31: 1284-1292.
5.WHO, Health C. Consultation on Serological Criteria for evaluation and licensing of new Pneumococcal Vaccines. Ottawa, Canada. Meeting Report, 7-8 July, 2008, Contract No.: Document Number
6. Dotres CP, Puga R, Ricardo Y, Broño CR, Paredes B, Echemendía V, Rosell S, González N, García-Rivera D, Valdés Y; Laboratory-Pneumococci Group; Havana-Pneumococci Group, Goldblatt D, Vérez-Bencomo V. Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: A randomized phase I clinical trial. Vaccine. 2014 Sep 15; 32(41):5266-70
7.Thompson A, Gurtman A, Patterson S, Juergens C, Laudat F, Emini EA, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013; 31(45):5289-95.
8.Fleming-Dutra KE, Conklin L, Loo JD, Knoll MD, Park DE, Kirk J, Goldblatt D, Whitney CG, O’Brien KL: Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. The Pediatric infectious disease journal 2014, 33(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S152.
9.Loo JD, Conklin L, Fleming-Dutra KE, Knoll MD, Park DE, Kirk J, et al. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. The Pediatric infectious disease journal. 2014; 33:S161-S71.
10. Park DE, Johnson TS, Nonyane BAS, Chandir S, Conklin L, Fleming-Dutra KE, et al. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. The Pediatric infectious disease journal. 2014; 33(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S130.
11. Word Health Organization. Pneumococcal vaccines WHO position paper–2012–recommendations. Vaccine. 2012; 30(32):4717-8.
12. Toraño-Peraza G, Pías-Solis L, Abreu-Capote M, Rodríguez-Ortega M, Dickinson-Meneses F, Varcárcel-Sánchez M. Serotipos y resistencia antimicrobiana de aislamientos meníngeos de Streptococcus pneumoniae. Cuba, 2007-2012. Vaccimonitor. 2014; 23(3):117-23.
13. Dickinson Meneses Felix ROM, Toraño Peraza Gilda. Pneumococcal meningitis in Cuban children and adolescents: A fifteen years follow up. Pediatrics Research International Journal. 2015;Vol. 2015. doi: 10.5171/2015.
14.Verez-Bencomo V, editor. Cuban pneumococcal conjugate vaccine: A new more cost-effective PCV7 in a PCV 13 era. 2nd SYMPOSIUM PNEUMOCOCCAL VACCINES VaccinePharma 2015; Varadero, Cuba.
15. González N, Paredes B, Pérez S, Mirabal M, Rivero I, González C, et al. Safety and immunogenicity of Cuban antipneumococcal conjugate vaccine PCV7-TT in healthy adults. MEDICC Review. 2015; 17(4):32-7.
16.Kapasi A.,Mead Bruce., Brian Plikaytis.,Pawloski L., Martin MO.,et al. Comparative study of Different sorces of Pertussis Toxin (PT) as Coating Antigens in IgG Anti- PT Enzyme – Linked Immunosorbent Assays.Clinical and Vaccine Immunology:April 2015,64-72
17. K.A. Bryanta, R. Frenckb, A. Gurtmanc, J. Rubinod, J. Treanore, A. Thompsonc, T.R. Jonesc,V. Sundaraiyerf, L.M. Baxterg, W.C. Gruberc, E.A. Eminih, D.A. Scottc, B. Schmoele-Thomaia. Immunogenicity and safety of a 13-valent pneumococcal conjugatevaccine in adults 18–49 years of age, naive to 23-valent pneumococcalpolysaccharide vaccine. Vaccine 33 (2015) 5854–5860
18.E Susanna, T Susan, Thompson Allison, et al. Safety and Immunogenicity of a 13-Valent Pneumococcal ConjugateVaccine Compared to Those of a 7-Valent Pneumococcal ConjugateVaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers. Clinical and Vaccine Immunology, June 2010, p. 1017–1026.
19.JRuiz-Aragón, S. Márquez Peláezb, J.M. Molina-Lindeb, A.M. Grande-Tejadac. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis. Vaccine 31 (2013) 5349– 5358
20.G Jane, T Anna, T William, H Scott A, C Angela et al. Immunization site pain: Case definition and guidelines for collection, analysis, and presentation of immunization safety data The Brighton Immunization Site Pain Working Group. Vaccine 2012.